Dry AMD

oral supplementation (Macuprev) 2 capsules per day for 6 months

Macuprev Group

oral placebo 2 capsules per day for 6 months

Placebo Group

Fondazione G.B.Bietti

Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.

Evaluation of Macular Function and Related Changes in Visual Perception and Retinal Morphology After 6 Months of Use of Oral Supplementation Called MACUPREV, in Patients With Dry Age-related Macular Degeneration (AMD)

To evaluate functional retinal changes of the macular region by multifocal electroretinogram in patients with dry age-related macular degeneration after the use for 6 months of an oral supplementation in tablets based on Ganoderma lucidum (Reishi), Calendula Officinalis, Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid, Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper.
The researchers analyzed the average response amplitude densities (RAD: nanoV/ degree 2) between the first negative peak, N1 and the first positive peak, P1

The researchers evaluated the linear relationships between the mfERG (Response Amplitude Density (RAD nanoV/degree2) and OCT/OCTA values (CRT in micron and vessel density in mm3) by Pearson's Test after administration of a oral supplementation (Macuprev)

Mariacristina Parravano

Head Retina Unit

Fondazione G.B. Bietti, IRCCS

monocentric, prospective, double blind randomized six months study

All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.

All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the

Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study

Age-Related Macular Degeneration

alpha lipoic acid

Placebo

University of Iowa Hospitals and Clinics, Department of Ophthalmology & Visual Sciences

NJ Retina

Oregon Regina. LLP

Retina Northwest, P.C.

Scheie Eye Institute of the University of Pennsylvania

Alpha Lipoic Acid in Geographic Atrophy

Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD).

The percent of adverse events that develop will be stratified by the alpha lipoic acid dose.

alpha lipoic acid/atrofie

Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.

Alpha Lipoic Acid in Geographic Atrophy

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap